Cargando…
DNA损伤修复与肺癌顺铂耐药机制的研究进展
Lung cancer is the most common cause of death from cancer worldwide per year.Platinum-based combination chemotherapy is a main treatment of lung cancer.Cisplatin is adopted widely and used effectively in the first-line chemotherapy.Unfortunately, development of cisplatin resistance is a major obstac...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000195/ https://www.ncbi.nlm.nih.gov/pubmed/22152698 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.12.11 |
_version_ | 1783331639494967296 |
---|---|
collection | PubMed |
description | Lung cancer is the most common cause of death from cancer worldwide per year.Platinum-based combination chemotherapy is a main treatment of lung cancer.Cisplatin is adopted widely and used effectively in the first-line chemotherapy.Unfortunately, development of cisplatin resistance is a major obstacle to the success of lung caner.Cisplatin is a cell-cycle-non-specific cytotoxic drugs and its main target is DNA.Thus, defective DNA damage repair is one of the main mechanisms of cisplatin resistance.In this review, we will focus on the defective DNA damage repair in cisplatin resistance of lung cancer including nucleotide excision repair, DNA mismatch repair, DNA double-strand break repair and translesion synthesis. |
format | Online Article Text |
id | pubmed-6000195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60001952018-07-06 DNA损伤修复与肺癌顺铂耐药机制的研究进展 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the most common cause of death from cancer worldwide per year.Platinum-based combination chemotherapy is a main treatment of lung cancer.Cisplatin is adopted widely and used effectively in the first-line chemotherapy.Unfortunately, development of cisplatin resistance is a major obstacle to the success of lung caner.Cisplatin is a cell-cycle-non-specific cytotoxic drugs and its main target is DNA.Thus, defective DNA damage repair is one of the main mechanisms of cisplatin resistance.In this review, we will focus on the defective DNA damage repair in cisplatin resistance of lung cancer including nucleotide excision repair, DNA mismatch repair, DNA double-strand break repair and translesion synthesis. 中国肺癌杂志编辑部 2011-12-20 /pmc/articles/PMC6000195/ /pubmed/22152698 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.12.11 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title | DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title_full | DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title_fullStr | DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title_full_unstemmed | DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title_short | DNA损伤修复与肺癌顺铂耐药机制的研究进展 |
title_sort | dna损伤修复与肺癌顺铂耐药机制的研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000195/ https://www.ncbi.nlm.nih.gov/pubmed/22152698 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.12.11 |